Effect of Azithromycin in Preventing Premature Labour
Study Details
Study Description
Brief Summary
This is a prospective observational case controlled study. The control group will include pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy.
The test group will involve pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Detailed Description
A prospective randomized clinical study was conducted in the outpatient clinic of the gynecology department of Beni Suef University Hospital, Beni-Suef, Egypt, between October 01, 2021, and April 30, 2022. The study included 211 pregnant women aged between 20 to 41 years. These patients were randomized into three groups.
The first group which was the control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy. While the second group which was the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month.
. The third group was the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Control group control group, included pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments (progesterone) for prolongation of pregnancy. |
|
Azithromycin group the first test group, involved pregnant women, having intact membranes and are at risk of or in preterm labour, administrating the standard treatments for prolongation of pregnancy plus azithromycin for 5 days every month |
Drug: Azithromycin
The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
|
Azithromycin plus Clindamycin group the second test group in which the pregnant women administerated Azithromycin and clindamycin (Dalacin®) vaginal gel 5 times per month. |
Drug: Azithromycin
The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
|
Outcome Measures
Primary Outcome Measures
- Effect of Azithromycin in preventing premature labour [6 monthes]
Main outcome was the number of days between diagnosis and composite event, defined as delivery or rupture of membranes or 2nd intervention aimed at prolonging pregnancy (such as cerclage or tocolysis) or censure (maternal death or transfer). The three groups were compared regarding this number of days
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pregnant women with <34 weeks of gestation,
-
Hospitalization for risk of preterm labour,
-
Threat of preterm labour, or preterm labour itself.
-
Threat of preterm labour and preterm labour will have to be diagnosis cited in the medical record by the physician.
-
Women at risk of preterm labour must have one of the following conditions cited in their record: sludge, short cervix, cerclage, or bulging membranes
Exclusion Criteria:
- Patients were excluded from the current study in case of the use of antibiotics within 14 days before the admission (except for pericerclage prophylaxis, or streptococcus B prophylaxis), PPROM or fetal extraction required <37 weeks.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Beni-Suef University teaching Hospital | Banī Suwayf | Beni-Suef | Egypt | 62511 |
Sponsors and Collaborators
- Beni-Suef University
Investigators
- Principal Investigator: Raghda R.S Hussein, Beni-Suef University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- REC-H-PhBSU-21022